Systematic review on quality control for drug management programs: Is quality reported in the literature?

BMC Health Services Research

Volumn 9, Issue , 2009, Pages

  Holtorf, Anke Peggy ^a   McAdam Marx, Carrie ^a   Schaaf, David ^b   Eng, Benjamin ^b   Oderda, Gary ^a  

^a UNIVERSITY OF UTAH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE QUALITY; HUMAN; MEDICATION THERAPY MANAGEMENT; REVIEW; STANDARD; UNITED STATES;

HUMANS; MEDICATION THERAPY MANAGEMENT; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 62149139648     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-9-38     Document Type: Article

References (89)

1. Measuring the quality of health care: a statement by the National Roundtable on Health Care Quality. Institute of Medicine, Washington, DC: National Academy Health 1999
2. The AMCP Format for Formulary Submissions: Version 2. Academy of Managed Care Pharmacy, 2005
3. National Voluntary Consensus Standards for the Reporting of Therapeutic Drug Management Quality. National Quality Forum, 2006
4. eValue8 Health Care. http://www.evalue8.org/eValue8/index.cfm
5. Pharmacy Benefit Management Accreditation. URAC, 2007
6. Cost containment strategies for prescription drugs: assessing the evidence in the literature. http://www.kff.org
7. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. DP Goldman GF Joyce Y Zheng, Jama 2007 298 61 69 10.1001/jama.298.1.61 17609491
8. Evaluating the nondrug costs of formulary coverage restrictions. P Abourjaily WA Gouveia HP Selker DR Zucker, Manag Care 2005 14 50 57 62 16173282
9. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. S Abughosh S Kogut S Andrade P Larrat J Gurwitz, J Manag Care Pharm 2004 10 404 411 15369423
10. Use of antihypertensive drugs by Medicare enrollees: does type of drug coverage matter? AS Adams SB Soumerai D Ross-Degnan, Health Aff 2001 20 276 286 10.1377/hlthaff.20.1.276
11. The case for a Medicare drug coverage benefit: a critical review of the empirical evidence. AS Adams SB Soumerai D Ross-Degnan, Annu Rev Public Health 2001 22 49 61 10.1146/annurev.publhealth.22.1.49 11274510
12. Impact of Generosity Level of Outpatient Prescription Drug Coverage on Prescription Drug Events and Expenditure Among Older Persons. MB Artz RS Hadsall SW Schondelmeyer, Am J Public Health 2002 92 1257 1263 12144981 10.2105/AJPH.92.8.1257
13. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. J Berger, Am J Manag Care 2007 13 Suppl 2 S55 58 17417934
14. Three-Tiered-Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs. B Briesacher S Kamal-Bahl M Hochberg D Orwig KH Kahler, Arch Intern Med 2004 164 1679 1684 10.1001/archinte.164.15.1679 15302639
15. Effects of benefit design change across 5 disease states. DI Brixner VN Joish GM Odera SG Avey DM Hanson HE Cannon, Am J Manag Care 2007 13 370 376 17567238
16. The economic burden associated with prior authorizations in an allergist office. Bukstein A Don Cherayil A Greeta Gepner D Adam Luskin T Allan Kooistra J Brent, Allergy Asthma Proc 2006 27 2 119 122 16724629
17. Comparison of costs of community and mail service pharmacy. NV Carroll I Brusilovsky B York R Oscar, Journal of the American Pharmacists Association 2005 45 336 343 10.1331/1544345054003796 15991755
18. Effects Of Generic-Only Drug Coverage In A Medicare HMO. J Christian-Herman M Emons D George, Health Aff (Millwood) 2004 Suppl Web Exclusives W4-455 W468 15471765
19. Health plan member experience with point-of-service prescription step therapy. E Cox R Henderson B Motheral, J Manag Care Pharm 2004 10 4 291 298 15298527
20. Medicare beneficiaries' management of capped prescription benefits. E Cox C Jernigan S Coons J Draugalis, Med Care 2001 39 296 301 10.1097/00005650- 200103000-00009 11242323
21. Determinants of satisfaction with prescription drug plans. SP Desselle, Am J Health Syst Pharm 2001 58 1110 1119 11449854
22. Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system. JD Dunn HE Cannon, Manag Care Interface 2006 19 46 51 16786970
23. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. KA Fairman BR Motheral RR Henderson, Clinical Therapeutics 2003 25 3147 3161 10.1016/S0149-2918(03)90099-3 14749153
24. Is prior authorization of topical tretinoin for acne cost effective? SR Feldman ABJ Fleischer GJ Chen, Am J Manag Care 1999 5 457 463 10387385
25. Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid. KS Fink PJ Byrns, Ann Fam Med 2004 2 488 493 15506586 10.1370/afm.121
26. Economic Consequences of Underuse of Generic Drugs: Evidence from Medicaid and Implications for Prescription Drug Benefit Plans. MA Fischer J Avorn, Health Services Research 2003 38 1051 1064 12968816 10.1111/1475-6773. 00162
27. Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors. MA Fischer S Schneeweiss J Avorn DH Solomon, N Engl J Med 2004 351 2187 2194 10.1056/NEJMsa042770 15548779
28. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. O Gershovich S Billups T Delate C Hoffman N Carroll, J Manag Care Pharm 2006 12 246 253 16623609
29. The Effects of Prescription Drug Copayments on Statin Adherence. T Gibson T Mark K McGuigan K Axelsen S Wang, The American Journal of Managed Care 2006 12 509 517 16961440
30. Impact of statin copayments on adherence and medical care utilization and expenditures. TB Gibson TL Mark K Axelsen O Baser DA Rublee KA McGuigan, Am J Manag Care 2006 12 Spec no SP11 19 17173486
31. The Effects of Prescription Drug Cost Sharing: A Review of the Evidence. TB Gibson RJ Ozminkowski RZ Goetzel, Am J Manag Care 2005 11 730 740 16268755
32. Consumer response to dual incentives under multitiered prescription drug formularies. BH Gilman J Kautter, Am J Manag Care 2007 13 353 359 17567236
33. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. D Goldman G Joyce K-M P, Am J Manag Care 2006 12 21 28 16402885
34. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. BN Harris DS West JT Johnson SH Hong CD Stowe, J Manag Care Pharm 2004 10 449 455 15369428
35. An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan. DM Hartung KL Ketchum DG Haxby, Health Aff (Millwood) 2006 25 1423 1432 10.1377/hlthaff.25.5.1423 16966742
36. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care medicaid population. DM Hartung DR Touchette KL Ketchum DG Haxby BW Goldberg, Clinical Therapeutics 2004 26 1518 1532 10.1016/j.clinthera.2004.09.013 15531015
37. Financial incentives and drug spending in managed care. AL Hillman MV Pauly JJ Escarce K Ripley M Gaynor J Clouse R Ross, Health Aff 1999 18 189 200 10.1377/hlthaff.18.2.189
38. Unintended Consequences of Caps on Medicare Drug Benefits. J Hsu M Price J Huang R Brand V Fung R Hui B Fireman JP Newhouse JV Selby, N Engl J Med 2006 354 2349 2359 10.1056/NEJMsa054436 16738271
39. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. HA Huskamp PA Deverka AM Epstein RS Epstein KA McGuigan RG Frank, N Engl J Med 2003 349 2224 2232 10.1056/NEJMsa030954 14657430
40. Impact of 3-Tier Formularies on Drug Treatment of Attention-Deficit/ Hyperactivity Disorder in Children. HA Huskamp PA Deverka AM Epstein RS Epstein KA McGuigan AC Muriel RG Frank, Arch Gen Psychiatry 2005 62 435 441 15809411 10.1001/archpsyc.62.4.435
41. The Effect of Increased Prescription Drug Cost-Sharing on Medical Care Utilization and Expenses of Elderly Health Maintenance Organization Members. RE Johnson, Medical Care 1997 35 1119 1131 10.1097/00005650-199711000-00004 9366891
42. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans. M Johnsrud KA Lawson MD Shepherd, J Manag Care Pharm 2007 13 122 134 17330973
43. Employer Drug Benefit Plans and Spending on Prescription Drugs. GF Joyce JJ Escarce MD Solomon DP Goldman, JAMA 2002 288 1733 1739 10.1001/jama.288.14. 1733 12365957
44. How Do Incentive-Based Formularies Influence Drug Selection And Spending For Hypertension? S Kamal-Bahl B Briesacher, Health Aff 2004 23 227 236 10.1377/hlthaff.23.1.227
45. The effects of copayments on medication adherence during the first two years of prescription drug treatment. RC Kessler CR Cantrell P Berglund MC Sokol, J Occup Environ Med 2007 49 597 609 10.1097/JOM.0b013e318057772b 17563602
46. Incentive formularies and changes in prescription drug spending. BE Landon MB Rosenthal SL Normand C Spettell A Lessler HR Underwood JP Newhouse, Am J Manag Care 2007 13 360 369 17567237
47. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. P Landsman W Yu X Liu S Teutsch M Berger, Am J Manag Care 2005 11 621 628 16232003
48. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. JT Lurk DJ DeJong TM Woods ME Knell CA Carroll, Am J Health Syst Pharm 2004 61 267 272 14986557
49. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate. DE Mager ER Cox, Am J Manag Care 2007 13 347 352 17567235
50. Lowering patient drug acquisition costs to improve health outcomes and costs. J Mahoney, Manag Care Interface 2006 19 13 16689022
51. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. JS McCombs L Shi GL Stimmel TW Croghan, Clinical Therapeutics 2002 24 1939 1959 10.1016/S0149-2918(02)80090-X 12501884
52. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. B Meissner M Dickson J Shinogle CE Reeder D Belazi V Senevirante, J Manag Care Pharm 2006 12 331 340 16792439
53. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids. BL Meissner WM Moore JA Shinogle CE Reeder JM Little, J Manag Care Pharm 2004 10 226 233 15228372
54. Medication Costs, Adherence, And Health Outcomes Among Medicare Beneficiaries. R Mojtabai M Olfson, Health Aff 2003 22 220 229 10.1377/hlthaff.22.4.220
55. Improving Prescribing Patterns for the Elderly Through an Online Drug Utilization Review Intervention: A System Linking the Physician, Pharmacist, and Computer. M Monane DM Matthias BA Nagle MA Kelly, JAMA 1998 280 1249 1252 10.1001/jama.280.14.1249 9786375
56. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. B Motheral K Fairman, Med Care 2001 39 1293 1304 10.1097/00005650-200112000-00005 11717571
57. Predictors of satisfaction of health plan members with prescription drug benefits. BR Motheral SM Heinle, Am J Health Syst Pharm 2004 61 1007 1014 15160776
58. Plan-sponsor savings and member experience with point-of-service prescription step therapy. BR Motheral R Henderson ER Cox, Am J Manag Care 2004 10 457 464 15298367
59. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. B Motheral R Henderson, Am J Manag Care 1999 5 1383 1394 10662412
60. The effect of switching on compliance and persistence: the case of statin treatment. P Thiebaud BV Patel MB Nichol DM Berenbeim, Am J Manag Care 2005 11 670 674 16268750
61. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. MM Murawski T Abdelgawad, Am J Manag Care 2005 11 Spec No SP35 42 15700908
62. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states. K Nair J Ganther R Valuck M McCollum S Lewis, J Manag Care Pharm 2002 8 477 491 14613381
63. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. K Nair P Wolfe R Valuck M McCollum J Ganther S Lewis, J Manag Care Pharm 2003 9 123 133 14613341
64. Managed care organization's experience with a therapeutic conversion program in hypertensive patients. T Oh SS Mehta C Bonanno, ASHP-Annual Meeting 1999 1999 56 Jun 51
65. Consumer understanding and satisfaction associated with a 3-tier prescription drug benefit. B Olson D Malone W Zachary S Coons, J Manag Care Pharm 2004 11 6 480 492 15998165
66. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. PE Panzer TS Regan E Chiao MW Sarnes, Am J Manag Care 2005 11 S370 379 16236019
67. Effect of tiered prescription copayments on the use of preferred brand medications. TS Rector MD Finch PM Danzon MV Pauly M BS, Med Care 2003 41 398 406 10.1097/00005650-200303000-00008 12618643
68. A Review of Prior Authorization Programs: Antihemophilic, Antineoplastic, and Antiretroviral Agents. K Richards M Johnsrud M Shepherd, The Center for Pharmacoeconomic Studies 2004
69. Economic and clinical outcomes following application of a cholesterol population model in a closed class formulary decision. MA Richerson JR Downs D Remund, ASHP-Annual Meeting; 2001 2001 58 Jun 39E
70. Consumer knowledge and perceptions of formularies. SS Sansgiry S Sikri A Kawatkar, Manag Care Interface 2004 17 21 26 30 15035596
71. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. MM Spence R Hui J Chan, J Manag Care Pharm 2006 12 377 382 16792444
72. Impact of a formulary switch from amlodipine to felodipine at a VA medical center. MS Sprague DR Gray, ASHP-Midyear Clinical Meeting; 1998 1998 33 Dec 424E
73. The Effect of the Rx-to-OTC Switch of Loratadine and Changes in Prescription Drug Benefits on Utilization and Cost of Therapy. PW Sullivan KV Nair BV Patel, Am J Manag Care 2005 11 374 382 15974556
74. Pharmacy costs associated with nonformulary drug requests. BV Sweet JG Stevenson, Am J Health Syst Pharm 2001 58 1746 1752 11571818
75. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. DA Taira KS Wong F Frech-Tamas RS Chung, Am J Manag Care 2006 12 678 683 17090224
76. Impact Of Health Plan Design And Management On Retirees' Prescription Drug Use And Spending, 2001. CP Thomas SS Wallack S Lee GA Ritter, Health Aff (Millwood) 2002 Suppl Web Exclusives W408 W419 12703602
77. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability. T Trygstad R Hansen S Wegner, J Manag Care Pharm 2005 12 2 108 120 16515369
78. Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients. C-W Tseng RH Brook E Keeler CM Mangione, JAMA 2003 290 222 227 10.1001/jama.290.2.222 12851277
79. Cost-Lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit Caps and Have a Gap in Drug Coverage. C-W Tseng RH Brook E Keeler WN Steers CM Mangione, JAMA 2004 292 952 960 10.1001/jama.292.8.952 15328327
80. Cost analysis of four benefit strategies for managing a Cox II inhibitor. G Tucker A Moore D Avant M Monteiro, Journal of Managed Care Pharmacy 2001 7 224 227
81. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. J Wilson K Axelsen S Tang, Am J Manag Care 2005 11 SP27 34 15700907
82. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. K Yokoyama W Yang R Preblick F Frech-Tamas, J Manag Care Pharm 2007 13 235 244 17407390
83. Effect of a medication copayment increase in veterans with schizophrenia. JE Zeber KL Grazier M Valenstein FC Blow PM Lantz, Am J Manag Care 2007 13 335 346 17567234
84. Pharmaceutical policies: effects of cap and co-payment on rational drug use. A Austvoll-Dahlgren M Aaserud G Vist C Ramsay AD Oxman H Sturm JP Kosters A Vernby, Cochrane Database Syst Rev 2008 CD007017 18254125
85. The effect of a three-tier formulary on antidepressant utilization and expenditures. D Hodgkin C Parks Thomas L Simoni-Wastila GA Ritter S Lee, J Ment Health Policy Econ 2008 11 67 77 18509214
86. Value based medicine. MM Brown GC Brown, Br J Ophthalmol 2004 88 979 15258007 10.1136/bjo.2003.040030
87. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007. CY Lu D Ross-Degnan SB Soumerai SA Pearson, BMC Health Serv Res 2008 8 75 18394200 10.1186/1472-6963-8-75
88. Preferred drug lists: potential impact on healthcare economics. K Ovsag S Hydery SA Mousa, Vasc Health Risk Manag 2008 4 403 413 18561515
89. Framework for pharmacy services quality improvement - a bridge to cross the quality chasm. Part I. The opportunity and the tool. FR Curtiss RN Fry SG Avey, J Manag Care Pharm 2004 10 60 78 14720106